Abstract 5697: Targeting PARP inhibitor resistance with Polθ inhibitors
Diana Zatreanu(Institute of Cancer Research), Christopher J. Lord(Institute of Cancer Research), Jayne Curry(Brigham and Women's Hospital), Theresia A. Schaedler(University of Cambridge), Rachel Brough(Institute of Cancer Research), Tennyson Ekwuru(Cancer Research UK), Rebecca Marlow(Institute of Cancer Research), Vera Grinkevich(Wellcome Sanger Institute), Graeme Hewitt(Newcastle Hospitals - Campus for Ageing and Vitality), Marco Ranzani(Wellcome Sanger Institute), Niall M.B. Martin, Elsa Callén(National Cancer Institute), André Nussenzweig(National Institutes of Health), Martin L. Stockley, Marie Boursier, Joana B. Neves(The Royal Free Hospital), Remko Prevo(University of Oxford), Joost Schimmel(Leiden University Medical Center), Graeme C. Smith, Jayesh B. Majithiya, Eleanor Knight(Cancer Research UK), Lerin Geo, Peter Blencowe(Cancer Research UK), Sophie Langdon(King's College London), Syed Haider(MRC Laboratory of Molecular Biology), Christopher Bot(Cancer Research UK), Aditi Gulati(Institute of Cancer Research), Christina Alli(Cancer Research UK), Mathew Calder(Cancer Research UK), Kimberley A. Wiggins, Marcel Tijsterman(Leiden University), Eeson Rajendra(Pharma Nord (United Kingdom)), Geoff S. Higgins(Oxford University Hospitals NHS Trust), Harry Finch(University of Liverpool), Helen M. Robinson(The University of Melbourne), Robert A. Heald, Cameron P. M. Bell, Amanda Ferdinand(Cancer Research UK), Luted Badder(Institute of Cancer Research), Omar Alkhatib, Stephen J. Pettitt(Gene Therapy Laboratory), Daniela Novo(Breast Cancer Research Foundation), Andrew Tutt(Institute of Cancer Research), Nan Shao(The First People's Hospital of Changzhou), Simon J. Boulton(The Francis Crick Institute), Mark Charles(Discovery Laboratories (United States)), Sandhya Sridhar(Institute of Cancer Research), Diego Grande, Shaun Moore, Claire McWhirter(AstraZeneca (United Kingdom))
Cited by 1
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k